Drugs / EZM0414
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05121103 | May 2022 → Apr 2024 | diffuse large B-cell lymphoma, plasma cell myeloma | Epizyme, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EZM0414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05121103 ↗ |
| Action | Inhibit | “SETD2 Inhibitor EZM0414” NCT05121103 ↗ |
| Modality | Small molecule | — CHEMBL5095235 ↗ |
| Route | Oral | “EZM0414 will be administered orally once daily (QD) without food.” NCT05121103 ↗ |
| Target | SETD2 | “SETD2 Inhibitor EZM0414” NCT05121103 ↗ |